ADVANCED CANCER

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. Participants had solid tumors that were no longer responding to standard treatments. The goal was to see if the vaccine was safe and feasible t…

This study tested a new drug called RP-6306 in 28 adults with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also checked if certain biomarkers made the drug work better.

This study tested a combination of two drugs, lenvatinib and eribulin, in 30 adults with advanced sarcoma (a type of cancer) that could not be removed by surgery or had spread. The goal was to see if the combo could shrink tumors or stop them from growing. Participants had alread…

This early-phase study tested the safety of combining several cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 people with advanced or metastatic solid tumors. The goal was to find safe doses for each combination to use in later studies. Participant…

This study tested an experimental drug called ART4215 in 93 people with advanced or metastatic solid tumors (cancers that have spread). The goal was to find a safe dose and see how well it works alone or combined with other cancer drugs (talazoparib or niraparib). Participants ha…

This study tested a new experimental drug called BMS-986249, given alone or together with the approved immunotherapy nivolumab, in 356 adults with advanced solid tumors (cancers that have spread or cannot be removed). The main goals were to check safety and find the best dose. Re…

This study tested whether the immunotherapy drug nivolumab could help prevent esophageal cancer from coming back after surgery. About 794 people who had surgery for stage II/III esophageal or gastroesophageal junction cancer received either nivolumab or a placebo. The main goal w…

This early-stage study tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had come back or stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers monitored side effects and how the dr…

This early-phase study tested a new drug called PTX-100 in 25 people with advanced cancers (like multiple myeloma, lymphoma, or pancreatic cancer) that had stopped responding to standard treatments. The goal was to find the safest dose and see how the drug works in the body. Whil…

This early-stage trial tested a new drug, NEV801, in 78 adults with advanced solid tumors who had no other treatment options. The main goal was to find the safest dose and check for side effects. Researchers also looked for any signs that the drug might shrink tumors.

This study tested an experimental drug called BMS-986288, given alone or with another drug (nivolumab), in 219 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Researchers also looked …

This early-phase study tested a new DNA-based treatment called SXRN in 8 people with advanced solid tumors who had no other standard options. The main goal was to check safety and find the best dose, not to cure the cancer. The treatment aims to control the disease, but patients …

This early-stage study tested a new drug called COM902, alone or with another drug (COM701), in 94 people with advanced cancers like ovarian, lung, colon, and multiple myeloma. The main goal was to check safety and find the best dose. While not a cure, the approach aims to contro…

This early-phase study tested a new drug called AGEN1777, given alone or with another cancer drug (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. This is a f…

This early-phase trial tested whether adding the drug pirfenidone to standard chemotherapy is safe and effective for people with advanced non-small cell lung cancer. 48 participants received the combination to find the best dose and see if tumors shrank. The goal was to control t…

This study tested a combination of two immunotherapy drugs, nivolumab and relatlimab, in 68 adults with advanced soft-tissue sarcoma. The goal was to see if the combo could shrink tumors or stop them from growing for at least 6 months. Participants had a specific immune feature i…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and check for side effects, while also looking at how the drug moves through…

This study tested three-drug combinations for people with advanced solid tumors that had spread or couldn't be removed. The goal was to see if adding relatlimab to other immune-boosting drugs was safe and could shrink tumors. 229 adults with various advanced cancers took part. Th…

This study tested whether adding the oral drug axitinib to standard sandostatin therapy could slow cancer growth in 256 people with advanced neuroendocrine tumors (non-pancreatic). Participants had tumors that were growing despite prior treatment. The main goal was to see how lon…

This study tested a program to help couples communicate better when one partner has advanced cancer. 440 patients and their partners took part, with half receiving the communication training and the other half receiving general healthy living information. The goal was to see if t…

This study tested whether a supportive video visit with an oncology nurse within three days of leaving the hospital helps advanced cancer patients feel more confident managing their health. 286 adults with advanced cancer took part. The goal was to see if this extra support impro…

This study looked at 42 adults with advanced solid tumors who were receiving or about to start immunotherapy (checkpoint inhibitors) and also needed palliative radiotherapy to ease symptoms like pain or breathing trouble. The goal was to see how safe and tolerable the combination…

This study looked at how people with advanced cancer decide to talk about and write down their wishes for medical care if their condition gets worse. Researchers offered patients two special conversations about their preferences and tracked who took part. The goal was to learn mo…

This study looked at 1,250 adults with advanced cancer who visited the emergency room to find out what factors are linked to dying within 90 days. Researchers checked medical records and lab results to create risk profiles. The goal is to help doctors identify patients who need e…